Adherex is interested in pursuing partnerships with larger and intermediate-sized pharmaceutical and biotechnology companies for the following programs:
Eniluracil- Eniluracil is a dihydropyrimidine dehydrogenase (DPD) inhibitor that was previously under development by GSK for oncology indications. Eniluracil is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’s most widely-used oncology agents.
ADH-1- ADH-1, our lead biotechnology compound, is anN-cadherinantagonist being developed for use in cancer, either alone or in combination with other therapies, such asanti-angiogenics, biologics, radiation and chemotherapy.
STS- Adherex is developing sodium thiosulfate (STS) to protect against the hearing loss often associated with platinum-based chemotherapies
Non-cancer assets– Adherex’s intellectual property portfolio includes technologies that may have application for various indications outside of oncology, including vascular pathologies such as restinosis, angiogenesis-dependent pathologies such as cardiac ischemia, and neurology pathologies such as demyelinating diseases
Companies interested in exploring partnering opportunities for any of these programs should contact Adherex at or 919-484-8484.